|
GB0706363D0
|
|
Improved producer cell line for the production of recombinant viral vector particles for gene therapy
|
|
GB0700736D0
|
|
Method for the production of a type 1 interferon in a transgenic avian
|
|
GB0619815D0
|
|
Multisubtype interferon alpha for use as an immunological adjuvant
|
|
GB0619814D0
|
|
Interferon alpha-14 for use as an immunological adjuvant
|
|
GB0619816D0
|
|
Novel interferon-alpha constructs for use in the treatment of cancer
|
|
GB0609410D0
|
|
Method for the production of a type 1 interfemon in a transgenic avian
|
|
WO2006111745A2
|
|
Composition and method for treating viral infection
|
|
WO2006085092A2
|
|
Methods and uses of antibodies in the purification of interferon
|
|
GB0522732D0
|
|
Composition and method for treating disease
|
|
US2008120732A1
|
|
Method for Improved Transgene Expression
|
|
GB0509576D0
|
|
Ovalbumin promoter constructs for retroviral vectors
|
|
GB0509563D0
|
|
Composition
|
|
GB0508963D0
|
|
Composition
|
|
GB0507963D0
|
|
Composition and method for treating disease
|
|
GB0502991D0
|
|
Purification of interferon alpha using a monoclonal antibody
|
|
GB0502341D0
|
|
Composition
|
|
US2006280723A1
|
|
Interferon for treating or preventing a coronaviral infection
|
|
GB0402224D0
|
|
Composition
|
|
GB0320018D0
|
|
Composition
|
|
GB0303700D0
|
|
Antibody construct exhibiting increased homophilic binding
|
